CANDESARTAN/HCT SANDOZ 32/12.5mg candesartan cilexetil/hydrochlorothiazide 32mg/12.5mg tablet blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

candesartan/hct sandoz 32/12.5mg candesartan cilexetil/hydrochlorothiazide 32mg/12.5mg tablet blister pack

sandoz pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: iron oxide yellow; lactose monohydrate; povidone; carrageenan; magnesium stearate; croscarmellose sodium; iron oxide red; iron oxide black; maize starch - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

CANDESARTAN HCTZ AN 32/12.5 candesartan cilexetil 32 mg & hydrochlorothiazide 12.5 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

candesartan hctz an 32/12.5 candesartan cilexetil 32 mg & hydrochlorothiazide 12.5 mg tablet bottle

amneal pharma australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; macrogol 8000; lactose monohydrate; carmellose calcium; hyprolose; iron oxide yellow - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

CANDESARTAN HCTZ AN 32/25 candesartan cilexetil 32 mg & hydrochlorothiazide 25 mg tablet bottle Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

candesartan hctz an 32/25 candesartan cilexetil 32 mg & hydrochlorothiazide 25 mg tablet bottle

amneal pharma australia pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; carmellose calcium; hyprolose; macrogol 8000; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

CANDESARTAN HCTZ AGH 16/12.5 candesartan cilexetil 16 mg & hydrochlorothiazide 12.5 mg tablet blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

candesartan hctz agh 16/12.5 candesartan cilexetil 16 mg & hydrochlorothiazide 12.5 mg tablet blister pack

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: macrogol 8000; hyprolose; carmellose calcium; maize starch; lactose monohydrate; magnesium stearate; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

BTC CANDESARTAN candesartan cilexetil 16mg tablet blister pack Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

btc candesartan candesartan cilexetil 16mg tablet blister pack

sandoz pty ltd - candesartan cilexetil, quantity: 16 mg - tablet - excipient ingredients: magnesium stearate; maize starch; titanium dioxide; carrageenan; iron oxide red; povidone; croscarmellose sodium; lactose monohydrate - treatment of hypertension. . treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40percent) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

Candesartan/Amlodipine Krka 16 mg - 5 mg tabl. Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

candesartan/amlodipine krka 16 mg - 5 mg tabl.

krka d.d. novo mesto d.d. - candesartan cilexetil 16 mg; amlodipine besilate 6,94 mg - eq. amlodipine 5 mg - tablet - 16 mg - 5 mg - candesartan cilexetil 16 mg; amlodipine besilate 6.94 mg - candesartan and amlodipine

CANDESARTAN tablet Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

candesartan tablet

macleods pharmaceuticals limited - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx) - candesartan cilexetil 4 mg - candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure